PIK3CA and neoplasm: PIK3CA CN gain is reported to occur preferentially in PIK3CA mutant tumours potentially leading to more aggressive disease and a different response to treatment with supporting the hypothesis of a potential additive effect of mutations and gain to oncogenesis.